Cancer Immunotherapy

David B. Teplow

2024年10月 · Progress in Molecular Biology and Translational Science 第 209 冊 · Elsevier

電子書

300

頁

符合資格

評分和評論未經驗證瞭解詳情

關於本電子書

Cancer Immunotherapy, Volume 209 covers the progress that has been made in cancer immunotherapy. This volume surveys exciting developments in the field while also highlighting its promise and problems. Chapters in this release include The Promise, Progress, and Challenges of In Situ Immunization Agents in Cancer Immunotherapy, Breakthroughs in Synthetic Controlling Strategies for Precision in CAR-T Therapy, Non-coding RNAs in cancer immunotherapy: a solution to overcome immune resistance?, Rational Design of adjuvants boosts cancer vaccines, Emerging Drug delivery systems to alter Tumor immunosuppressive microenvironment: overcoming the challenges in immunotherapy for Glioblastoma.Other chapters cover Magnetic Nanoparticles: An Emerging Nanomedicine for Cancer Immunotherapy and Clinical and basic science aspects of innate lymphoid cells as novel immunotherapeutic targets in cancer treatment. - Discusses immune surveillance of tumors and how it is compromised - Presents new approaches to the development and delivery of cancer vaccines and cytotoxic T-cells to the tumor site - Demonstrates how new molecular biological approaches may augment the efficacy of CAR-T cells and dampen the effects of non-coding RNAs

關於作者

David B. Teplow, Ph.D., is a Professor of Neurology, Emeritus, at UCLA and an internationally recognized leader in efforts to understand and treat Alzheimer's disease. Dr. Teplow's group has used a multi-disciplinary approach to determine how neurotoxic peptides, such as the amyloid β-protein (Alzheimer's disease) and α-synuclein (Parkinson’s disease), form neurotoxic structures that kill neurons and to develop the means to block these processes. Dr. Teplow received undergraduate training at UC Berkeley; a Ph.D. from the University of Washington; and was a postdoctoral scholar at Caltech. Before coming to UCLA, Dr. Teplow was a faculty member in the Department of Neurology, Harvard Medical School. Dr. Teplow has published >250 peer-reviewed articles, books and book chapters, and commentaries, in addition to serving on numerous national and international scientific advisory boards. Dr. Teplow was a founding editor of the Journal of Molecular Neuroscience and Current Chemical Biology, He is Co-Editor-in-Chief of the Elsevier serial Progress in Molecular Biology and Translational Science and is Associate Editor-in-Chief of the American Journal of Neurodegenerative Disease.